Article

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

2021-04-09

Abstract excerpt

Background: Systemic therapies are typically combined with topical corticosteroids (TCS) in the management of moderate-to-severe atopic dermatitis (AD). Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 being developed for AD. AD Up was designed to assess the efficacy and safety of UPA+TCS versus placebo (PBO)+TCS in adolescent...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a24af233-0757-513f-ab2a-c6f9fbc2f8e4
DOI: 10.2139/ssrn.3748383

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)DOI 10.2139/ssrn.3748383Read

Efficacy Trajectory and Hematologic Safety of Oral JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Prospective Real-World StudySemantic proximity Read

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read

Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularisSemantic proximity Read

Navigating the atopic dermatitis toolbox: Challenging scenarios and shared decision-making.Semantic proximity Read

Efficacy and safety of tofacitinib in treatment of pemphigus: a single-center cohort studySemantic proximity Read

Impact of dupilumab and upadacitinib treatment on epigenetic and transcriptomic alterations in skin-homing T cells of atopic dermatitis patientsSemantic proximity Read

Inhibidores de JAK: usos en dermatología. Parte 2: aplicaciones en psoriasis, dermatitis atópica y otras dermatosisSemantic proximity Read

Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study.Semantic proximity Read

Targeting <scp>IL</scp>‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 yearsSemantic proximity Read

Association of demographic characteristics, aggravating factors, comorbidities and treatments with atopic dermatitis severitySemantic proximity Read

Efficacy and Safety of BBETTER PsoriaUrja in the Management of Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Trial ProtocolSemantic proximity Read

Optimizing outcomes for paediatric atopic dermatitis.Semantic proximity Read